Imperial partners in UK’s first total-body PET platform for drug discovery
Imperial researchers are partners in a UK initiative to improve clinical imaging for research and the development of new treatments.
Mapping the flow of healthcare data shows complex landscape
A comprehensive mapping and evaluation of electronic data flows in the NHS finds complex landscape and informs policy objectives.
Nanopore sequencing and DNA barcoding method gives hope of personalised medicine
With the ability to map dozens of biomarkers at once, a new method could transform testing for conditions including heart disease and cancer.
4
UN Science Summit heralds coming revolution in digital health diagnostics
Imperial together with its UK and African partners showcased the transformative potential of digital diagnostics at the recent UNGA Science Summit.
Feature
Imperial startups changing the world one tech at a time
Some of Imperial’s most exciting startups will showcase their innovative solutions at an event in San Franscisco this month.
New spinout to develop gene therapies targeting rare lung diseases
AlveoGene will work on gene therapies for several rare lung conditions, beginning with alpha-1 antitrypsin deficiency.
How old is your heart? AI predicts “heart age” and pinpoints link to genes.
Scientists develop a new AI tool which calculates ‘Heart Age’ more accurately than ever and helps pinpoint genes for ageing.
£1.5m ‘Quest for Cures’ grant to tackle aggressive brain tumours
An Imperial team engineering new techniques in cancer immunotherapy has been awarded £1.5m over five years.
Apollo Therapeutics raises $226.5m to develop medicines based on uni research
Company founded by the tech transfer offices of Imperial, Cambridge and UCL has raised major Series C funding to turn basic research into medicines.
Research sheds light on how breast cancer might develop after pregnancy
A study observing changes in healthy breast cells may explain why breast cancer might develop after pregnancy.
